Interaction Between COMT Genotype and MIND Diet, Cognitive Decline, and Incident Dementia: A Prospective Cohort Study
- 1Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA
- 2Department of Exercise and Nutrition Sciences, Milken Institute School of Public Health, The George Washington University, Washington, DC 20037, USA
- 3Rush Alzheimer’s Disease Center, Chicago, IL 60612, USA
Abstract
Background: Catechol-O-methyltransferase (COMT) metabolizes catecholamines and polyphenols unique to the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND). The COMT Val158Met variant modified the effect of MIND on change in perceptual speed after 3 years in a randomized controlled trial. We aimed to evaluate and extend these findings to dementia incidence in a community-based prospective cohort. Methods: We included 745 older adults (mean age 80.0 years) from the Rush Memory and Aging Project. MIND adherence was estimated using a validated food-frequency questionnaire (0–15 points). Repeated cognitive assessments and dementia diagnoses were based on standardized clinical neurological examinations and criteria. Linear regression, linear mixed-effects, and Cox proportional hazards models examined associations of COMT Val158Met and its interactions with MIND with baseline cognition, cognitive decline, and incident dementia. Associations with neuropathology and COMT protein were also explored. Results: Significant COMT × MIND interactions were observed for Alzheimer’s (p = 0.003) and all-cause (p = 0.004) dementia and for COMT × MIND × time interactions with declines in global cognition (p = 0.008), episodic memory (p = 0.009), and visuospatial ability (p = 0.01). Cognitive benefits associated with MIND adherence were greater among Met/Met carriers (lower COMT activity). The hazard ratio (95% CI) per MIND point for Alzheimer’s dementia was 0.82 (0.69–0.98) for Met/Met, 1.00 (0.87–1.15) for Met/Val, and 1.05 (0.84–1.33) for Val/Val. Greater MIND adherence was associated with lower plasma COMT (p = 0.01), while each additional Val allele was associated with higher brain COMT (p < 0.0001). Conclusions: Individuals with genetically reduced COMT activity may be especially responsive to cognitive benefits of the MIND diet. Further study is needed to determine whether these effects differ across cognitive domains.
Related
- Circulating osteocalcin and incident dementia in the UK Biobank: a prospective cohort and exploratory multi-omics analysis
- The choroid plexus, cognitive decline, and incident dementia: insights from the UK Biobank
- Association of platelet count with incident motoric cognitive risk syndrome among Chinese adults aged 60 years or older: a national prospective cohort study.
- The effect of herpes zoster vaccines on incident dementia in England: Protocol for an OpenSAFELY regression discontinuity study
- The Association Between APOE Genotype, Race, and Dementia: An Analysis of 7 Population-Based Cohort Studies
BibTeX
@article{cornelis2026interaction,
title = {{Interaction Between COMT Genotype and MIND Diet, Cognitive Decline, and Incident Dementia: A Prospective Cohort Study}},
author = {Marilyn C. Cornelis and Rob M. van Dam and David A. Bennett and Julie A. Schneider},
journal = {Nutrients},
year = {2026},
month = sep,
doi = {10.3390/nu18193232},
url = {https://europepmc.org/article/PMC/PMC13666954},
note = {CC BY},
}
RIS
TY - JOUR
TI - Interaction Between COMT Genotype and MIND Diet, Cognitive Decline, and Incident Dementia: A Prospective Cohort Study
AU - Marilyn C. Cornelis
AU - Rob M. van Dam
AU - David A. Bennett
AU - Julie A. Schneider
PY - 2026
DA - 2026/09/30
JO - Nutrients
DO - 10.3390/nu18193232
UR - https://europepmc.org/article/PMC/PMC13666954
AB - Background: Catechol-O-methyltransferase (COMT) metabolizes catecholamines and polyphenols unique to the Mediterranean-DASH Diet Intervention for Neurodegenerative Delay (MIND). The COMT Val158Met variant modified the effect of MIND on change in perceptual speed after 3 years in a randomized controlled trial. We aimed to evaluate and extend these findings to dementia incidence in a community-based prospective cohort. Methods: We included 745 older adults (mean age 80.0 years) from the Rush Memory and Aging Project. MIND adherence was estimated using a validated food-frequency questionnaire (0–15 points). Repeated cognitive assessments and dementia diagnoses were based on standardized clinical neurological examinations and criteria. Linear regression, linear mixed-effects, and Cox proportional hazards models examined associations of COMT Val158Met and its interactions with MIND with baseline cognition, cognitive decline, and incident dementia. Associations with neuropathology and COMT protein were also explored. Results: Significant COMT × MIND interactions were observed for Alzheimer’s (p = 0.003) and all-cause (p = 0.004) dementia and for COMT × MIND × time interactions with declines in global cognition (p = 0.008), episodic memory (p = 0.009), and visuospatial ability (p = 0.01). Cognitive benefits associated with MIND adherence were greater among Met/Met carriers (lower COMT activity). The hazard ratio (95% CI) per MIND point for Alzheimer’s dementia was 0.82 (0.69–0.98) for Met/Met, 1.00 (0.87–1.15) for Met/Val, and 1.05 (0.84–1.33) for Val/Val. Greater MIND adherence was associated with lower plasma COMT (p = 0.01), while each additional Val allele was associated with higher brain COMT (p < 0.0001). Conclusions: Individuals with genetically reduced COMT activity may be especially responsive to cognitive benefits of the MIND diet. Further study is needed to determine whether these effects differ across cognitive domains.
SN - 2072-6643
ER -